168 related articles for article (PubMed ID: 36010890)
1. Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting.
Kamal M; Navai N; Bree KK; Williams LA; Cleeland CS; Shen SE; Wang XS
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010890
[TBL] [Abstract][Full Text] [Related]
2. Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN).
Wang XS; Shi Q; Williams LA; Cleeland CS; Garcia-Gonzalez A; Chen TY; Shahid DR; Ramirez PT; Iniesta MD; Siverand AM; Meyer LA
Gynecol Oncol; 2019 Mar; 152(3):492-500. PubMed ID: 30876494
[TBL] [Abstract][Full Text] [Related]
3. Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep.
Wang XS; Shi Q; Williams LA; Lillemoe HA; Chen TY; Gottumukkala V; Garcia-Gonzalez A; Malveaux D; Kamal M; Cleeland CS; Aloia TA
Eur J Oncol Nurs; 2021 Jun; 52():101959. PubMed ID: 33964632
[TBL] [Abstract][Full Text] [Related]
4. Translation and validation of the Chinese version of the MD Anderson symptom inventory for measuring perioperative symptom burden in patients with gynecologic cancer.
Zhang T; Zheng YY; Yang ZR; Shi Q; Wang XS; Zhao J; Yang M; Wu CL; Wang GR
BMC Womens Health; 2021 Jul; 21(1):276. PubMed ID: 34325677
[TBL] [Abstract][Full Text] [Related]
5. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI).
Wang XS; Williams LA; Eng C; Mendoza TR; Shah NA; Kirkendoll KJ; Shah PK; Trask PC; Palos GR; Cleeland CS
Cancer; 2010 Apr; 116(8):2053-63. PubMed ID: 20166216
[TBL] [Abstract][Full Text] [Related]
6. Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study.
Wang XS; Bree KK; Navai N; Kamal M; Shen SE; Letona E; Cleeland CS; Shi Q; Gottumukkala V
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297013
[TBL] [Abstract][Full Text] [Related]
7. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory.
Mendoza TR; Wang XS; Lu C; Palos GR; Liao Z; Mobley GM; Kapoor S; Cleeland CS
Oncologist; 2011; 16(2):217-27. PubMed ID: 21285393
[TBL] [Abstract][Full Text] [Related]
8. Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module.
Piil K; Whisenant M; Mendoza T; Armstrong T; Cleeland C; Nordentoft S; Williams LA; Jarden M
Neurooncol Pract; 2021 Apr; 8(2):137-147. PubMed ID: 33898047
[TBL] [Abstract][Full Text] [Related]
9. Validation and Application of the MD Anderson Symptom Inventory for Traditional Chinese Medicine (MDASI-TCM).
Li Z; Shi Q; Liu M; Jia L; He B; Yang Y; Liu J; Lin H; Lin HK; Li P; Wang XS
J Natl Cancer Inst Monogr; 2017 Nov; 2017(52):. PubMed ID: 29140491
[TBL] [Abstract][Full Text] [Related]
10. The validity and utility of the M. D. Anderson Symptom Inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group.
Mendoza TR; Zhao F; Cleeland CS; Wagner LI; Patrick-Miller LJ; Fisch MJ
Clin Breast Cancer; 2013 Oct; 13(5):325-34. PubMed ID: 23816985
[TBL] [Abstract][Full Text] [Related]
11. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer.
Sailors MH; Bodurka DC; Gning I; Ramondetta LM; Williams LA; Mendoza TR; Agarwal S; Sun CC; Cleeland CS
Gynecol Oncol; 2013 Aug; 130(2):323-8. PubMed ID: 23685012
[TBL] [Abstract][Full Text] [Related]
12. Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module.
Armstrong TS; Gning I; Mendoza TR; Vera-Bolanos E; Gilbert MR; Rhines LD; Weinberg JS; Sanchez-Williams G; Levin V; Burton AW; Cleeland C
J Neurosurg Spine; 2010 Apr; 12(4):421-30. PubMed ID: 20367379
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy.
Wang XS; Srour SA; Mendoza T; Whisenant M; Subbiah I; Gonzalez E; Kamal M; Shen SE; Cleeland C; Kebriaei P; Rezvani K; Neelapu S; Ahmed S; Shpall E
Br J Haematol; 2023 May; 201(4):738-746. PubMed ID: 36733986
[TBL] [Abstract][Full Text] [Related]
14. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory.
Gning I; Trask PC; Mendoza TR; Harle MT; Gutierrez KA; Kitaka SA; Sherman SI; Cleeland CS
Oncology; 2009; 76(1):59-68. PubMed ID: 19052478
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
Mendoza TR; Williams LA; Keating KN; Siegel J; Elbi C; Nowak AK; Hassan R; Cuffel B; Cleeland CS
J Patient Rep Outcomes; 2019 Jun; 3(1):34. PubMed ID: 31209661
[TBL] [Abstract][Full Text] [Related]
16. Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module.
Tanaka S; Sato I; Takahashi M; Armstrong TS; Cleeland CS; Mendoza TR; Mukasa A; Takayanagi S; Narita Y; Kamibeppu K; Saito N
Jpn J Clin Oncol; 2020 Jul; 50(7):787-793. PubMed ID: 32280995
[TBL] [Abstract][Full Text] [Related]
17. Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID).
Williams LA; Whisenant MS; Mendoza TR; Peek AE; Malveaux D; Griffin DK; Ponce DA; Granwehr BP; Sheshadri A; Hutcheson KA; Ali SM; Peterson SK; Heymach JV; Cleeland CS; Subbiah IM
J Patient Rep Outcomes; 2023 May; 7(1):48. PubMed ID: 37237077
[TBL] [Abstract][Full Text] [Related]
18. Validation of the Spanish version of the MD Anderson symptom inventory - heart failure (MDASI-HF-Spanish) module.
Fadol A; Buitrago J; Diaz MC; Shelton V; Harty C; Mendoza TR
Cardiooncology; 2019; 5():19. PubMed ID: 32154025
[TBL] [Abstract][Full Text] [Related]
19. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module.
Jones D; Vichaya EG; Wang XS; Williams LA; Shah ND; Thomas SK; Johnson VE; Champlin RE; Cleeland CS; Mendoza TR
J Hematol Oncol; 2013 Feb; 6():13. PubMed ID: 23384030
[TBL] [Abstract][Full Text] [Related]
20. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
Williams LA; Whisenant MS; Mendoza TR; Haq S; Keating KN; Cuffel B; Cleeland CS
Qual Life Res; 2018 Dec; 27(12):3229-3241. PubMed ID: 30187393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
